Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 64

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 64
---
 price.

26

A summary of outstanding
warrants as of September 30, 2025 is as follows:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (in years)   Public and Private Placement Warrants   4,596   $23,000.00    3.38   February 2024 Series A Common Warrants   306    2,780.00    1.87   September 2024 Series C Common Warrants   4,088    0.80    2.46   December 2024 Common Warrants   4,203    112.20    2.73   January 2025 Common Warrants   8,193    116.40    2.77   February 2025 Pre-funded Warrants   10,787    0.002    No expiration date   February 2025 Common Warrants   127,551    39.20    4.36   Outstanding as of September 30, 2025   159,724   $707.39    4.14  

NOTE 10 – FAIR VALUE MEASUREMENTS

Investment in equity securities

On April 22, 2025, pursuant
to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth
PIPE Financing”), 6,250 shares of its Series D Preferred Stock to investors in exchange for the receipt of 1,000,279 shares of the
Stella Series D Preferred Stock, in which a portion of the Stella Series D Preferred Stock was owned by a related party investor (see
Note 13). The exchange of shares was in lieu of cash, the cost of which was initially included in investment in equity securities. The
fair value of Stella’s Series D Preferred Stock received was determined to be $500,000 as of the transaction date, based on the
subsequent sale of the 1,000,279 Stella Series D Preferred Stock $500,000 in cash, pursuant to a Stock Purchase Agreement dated August
20, 2025. Accordingly, the Company determined that the fair value of the equity securities on the date of the Fourth Securities Purchase
Agreement of April